NCT00404781

Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention

Pilot Study of Personal Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 305 (actual)
• Sponsor: Shenyang Northern Hospital · Academic / Other
• Sex: All
• Age: 35 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Effects of dual antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention has been proven. However, patients with low response to those agents are reported be associated with adverse clinical outcomes. We suppose that optimized antiplatelet therapy for individual patients based on platelet function assay may improve long-term outcomes especially in patients with high risk of thrombosis. In this prospective randomized study, patients in control group all receive standard dual antiplatelet therapy, and patients in optimized group receive different antiplatelet therapy according to risk stratification.

Conditions

• Ischemic Heart Disease
• Acute Coronary Syndromes

Interventions

Type	Name	Description
DRUG	cilostazol in addition to aspirin and clopidogrel

Timeline

• Start date: 2006-06-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2006-11-29
• Last updated: 2009-10-14

Locations

1 site across 1 country: China